12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Company News  |  Other News

Actavis, AstraZeneca cardiovascular news

AstraZeneca granted Actavis rights to sell Actavis' rosuvastatin zinc tablets and a generic version of AstraZeneca's cardiovascular drug Crestor rosuvastatin calcium beginning May 2, 2016. Actavis, formerly known as Watson Pharmaceuticals Inc., will pay the pharma 39% of net sales on...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >